Ma 2017.

Methods	Study design: Randomised clinical trial Study duration: May 2014 to June 2016 Duration of follow‐up: 1 year Setting: Hospital
Participants	Age (mean ± SD, range ): TACE + RFA: 55.04 ± 20.13 years, 35‐75 years; TACE: 54.56 ± 19.49 years, 35‐74 years Male (n/total): TACE + RFA: 21/35; TACE alone: 22/35 Tumour diameter (mean ± SD, range): TACE + RFA: 3.78 ± 2.25 cm, 1.5‐6.0 cm; TACE: 3.81 ± 2.21 cm, 1.6‐6.0 cm Child‐Pugh Class (patients): Class A: TACE + RFA: 18; TACE: 20 Class B: TACE + RFA: 17; TACE: 15
Interventions	TACE + RFA group (n = 35): TACE: Chemotherapeutic drugs: oxaliplatin and epirubicin RFA: The interval between TACE and RFA was 2‐3 weeks. RITA 1500 X system TACE group (n = 35): Chemotherapeutic drugs: oxaliplatin and epirubicin
Outcomes	Tumour response, according to WHO criteria, measured at 4 weeks after treatment Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.